Pharma BD Deal Intelligence
BMS's $4.1 billion cash acquisition of RayzeBio for its actinium-225 alpha-emitter platform, anchored by Phase 3 asset RYZ101 for neuroendocrine tumors. A June 2024 isotope supply shortage paused trial enrollment, though BMS's July 2025 Indianapolis manufacturing buildout has since de-risked the supply thesis.
BMS acquired RayzeBio for ~$4.1B for radiopharmaceutical development.
BMS and RayzeBio paused new-patient enrollment in the Phase 3 ACTION-1 trial of RYZ101 in June 2024 due to an actinium-225 isotope supply shortage;…
BMS opened a ~$160M, 77,000-sq-ft Indianapolis complex to produce actinium-225-based radiopharmaceutical cancer treatments; ribbon-cutting held July 11,…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Bristol Myers Squibb acquired RayzeBio (Nasdaq: RYZB) for $62.50 per share in cash, approximately $4.1 billion in equity value, in a deal announced December 26, 2023 and completed February 26, 2024. The acquisition gave BMS a differentiated actinium-225 (Ac-225) alpha-emitter radiopharmaceutical platform anchored by lead asset RYZ101 (225Ac-DOTATATE), a Phase 3 (ACTION-1) somatostatin-receptor-2-targeted therapy for SSTR2+ gastroenteropancreatic neuroendocrine tumors progressing after 177Lu somatostatin-analogue therapy, with additional development in extensive-stage small cell lung cancer and hepatocellular carcinoma. Post-close, the central execution risk has been Ac-225 isotope supply: BMS paused new ACTION-1 enrollment in June 2024 over a supply shortage, then in July 2025 opened a dedicated ~$160M, 77,000-sq-ft actinium radiopharmaceutical manufacturing facility in Indianapolis to vertically integrate clinical RYZ101 supply, materially de-risking the platform thesis.
The SSTR2+ GEP-NET market is anchored by somatostatin analogs (SSAs) and a single approved radioligand, with a deepening Actinium-225 race. Peptide receptor radionuclide therapy (PRRT): lutetium-177 DOTATATE (Lutathera, Novartis/AAA) is the incumbent FDA-approved therapy since 2018, generating ~$605M in 2023 per Novartis IR and setting the 3L benchmark after NETTER-1/NETTER-2. Next-generation alpha-PRRT: RYZ101 (225Ac-DOTATATE, BMS/RayzeBio) is in Phase 3 ACTION-1 post-Lutathera progression; 212Pb-DOTAMTATE (Perspective Therapeutics) and 225Ac-FPI-2059 (Fusion/AstraZeneca) are in Phase 2. Somatostatin analogs (1L/2L): octreotide LAR (Sandostatin LAR, Novartis) and lanreotide (Somatuline Depot, Ipsen) together exceeded ~$2.0B in 2023; pasireotide (Signifor LAR, Recordati) serves refractory cases. mTOR inhibitor: everolimus (Afinitor, Novartis) holds 2L/3L positioning across pancreatic NETs with well-established but modest efficacy. TKIs: sunitinib (Sutent, Pfizer) is approved for pNETs; cabozantinib (Cabometyx, Exelixis) received FDA approval in 2025 for advanced NETs based on CABINET. Commercial lead takeaway: RYZ101 is the most advanced alpha-emitter in a space defended by Lutathera economics; differentiation hinges on post-Lutathera durability and logistics of Ac-225 supply.
Advanced HCC is dominated by IO-based doublets in 1L with VEGF/MKI salvage, making RYZ801 (225Ac-GPC3) a differentiated-MOA entrant rather than a near-term first-line competitor. IO combinations (1L): atezolizumab + bevacizumab (Tecentriq + Avastin, Roche) is standard-of-care per IMbrave150; durvalumab + tremelimumab (Imfinzi + Imjudo, AstraZeneca) is approved via HIMALAYA; nivolumab + ipilimumab (Opdivo + Yervoy, BMS) gained 1L approval in 2025 after CheckMate-9DW. Multi-kinase inhibitors: sorafenib (Nexavar, Bayer), lenvatinib (Lenvima, Eisai/Merck — ~$2.4B global in 2023 across indications), and regorafenib (Stivarga, Bayer) as well as cabozantinib (Cabometyx, Exelixis) anchor 2L+. Anti-VEGFR2 mAb: ramucirumab (Cyramza, Eli Lilly) retains niche 2L use in AFP-high patients. Locoregional/radioligand precedent: Y-90 radioembolization (TheraSphere, Boston Scientific; SIR-Spheres, Sirtex) is standard for intermediate-stage disease; no systemic radioligand is yet approved in HCC. GPC3-targeted therapies: RYZ801 (Phase 1) competes with GC33 (codrituzumab, Roche — discontinued) and multiple GPC3 CAR-T programs (e.g., Carsgen CT011) in early-phase trials. Commercial lead takeaway: RYZ801 must demonstrate a post-IO/TKI activity signal in a GPC3-enriched subset to carve a 2L/3L biomarker-selected niche.
The ES-SCLC first-line standard is chemo-immunotherapy, with SSTR2 radiopharmaceuticals (RYZ101) positioned as a niche post-progression approach for SSTR2-positive subsets. Checkpoint inhibitors + platinum-etoposide: atezolizumab (Tecentriq, Roche) and durvalumab (Imfinzi, AstraZeneca) are the dominant 1L regimens following IMpower133 and CASPIAN; Imfinzi generated ~$4.7B in 2023 with ES-SCLC contributing a material share. DLL3-targeted bispecific: tarlatamab (Imdelltra, Amgen) received FDA accelerated approval May 2024 for 2L+ ES-SCLC based on DeLLphi-301, establishing a non-chemo post-progression benchmark. Chemotherapy backbones: topotecan (Hycamtin, Novartis/generic) and lurbinectedin (Zepzelca, Jazz) remain 2L workhorses; Zepzelca grossed ~$310M in 2023. PARP inhibitors: olaparib (Lynparza, AstraZeneca/Merck) and talazoparib (Talzenna, Pfizer) remain investigational in SCLC. Radioligand therapy: RYZ101 is the only Actinium-225 SSTR2 candidate in Phase 1b ES-SCLC, competing conceptually with lutetium-177 DOTATATE (Lutathera, Novartis) which is approved only in GEP-NETs. Commercial lead takeaway: RYZ101 faces a crowded 1L IO landscape but a structurally narrow 2L/3L field where SSTR2-selected biomarker positioning is plausibly defensible if response durability exceeds tarlatamab.
BMS completed $4.1B acquisition of RayzeBio ($62.50/share), gaining differentiated actinium-225 radiopharmaceutical platform and lead program RYZ101 for GEP-NETs.
BMS/RayzeBio paused new-patient enrollment in the Phase 3 ACTION-1 trial of RYZ101 over an actinium-225 isotope supply shortage (announced June 13, 2024); already-enrolled patients continued treatment.
BMS expanded radiopharma pipeline through RayzeBio, licensing OncoACP3 from Philochem for $350M upfront plus $1B milestones for prostate cancer.
BMS opened a ~$160M, 77,000-sq-ft Indianapolis radiopharmaceutical manufacturing facility producing clinical doses of RYZ101 and other actinium-225 therapies, vertically integrating the Ac-225 supply that had constrained the ACTION-1 trial.
BMS actively expanding RayzeBio's radiopharma platform with new deals. Isotope supply constraints remain a risk. RYZ101 Phase 3 ongoing. Too early for definitive verdict.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / RayzeBio Inc. (this deal) | 2023 | $4.1B | 68 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2023 deals · Bristol-Myers Squibb Company deals · Oncology deals